GH Research Past Earnings Performance
Past criteria checks 0/6
GH Research's earnings have been declining at an average annual rate of -55.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.
Key information
-55.2%
Earnings growth rate
-52.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -21.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How GH Research makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -41 | 13 | 35 |
| 30 Jun 24 | 0 | -35 | 12 | 34 |
| 31 Mar 24 | 0 | -32 | 11 | 31 |
| 31 Dec 23 | 0 | -36 | 11 | 30 |
| 30 Sep 23 | 0 | -41 | 11 | 28 |
| 30 Jun 23 | 0 | -36 | 10 | 26 |
| 31 Mar 23 | 0 | -28 | 10 | 23 |
| 31 Dec 22 | 0 | -22 | 10 | 20 |
| 30 Sep 22 | 0 | -10 | 11 | 17 |
| 30 Jun 22 | 0 | -11 | 11 | 15 |
| 31 Mar 22 | 0 | -14 | 9 | 13 |
| 31 Dec 21 | 0 | -9 | 7 | 9 |
| 30 Sep 21 | 0 | -5 | 3 | 5 |
| 30 Jun 21 | 0 | -4 | 1 | 3 |
| 31 Mar 21 | 0 | -2 | 1 | 1 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
Quality Earnings: 1KA is currently unprofitable.
Growing Profit Margin: 1KA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1KA is unprofitable, and losses have increased over the past 5 years at a rate of 55.2% per year.
Accelerating Growth: Unable to compare 1KA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1KA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 1KA has a negative Return on Equity (-21.88%), as it is currently unprofitable.